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Abstract
Whole genome sequencing (WGS) of Plasmodium vivax is problematic due to the reliance on clinical isolates which are
generally low in parasitaemia and sample volume. Furthermore, clinical isolates contain a significant contaminating
background of host DNA which confounds efforts to map short read sequence of the target P. vivax DNA. Here, we discuss a
methodology to significantly improve the success of P. vivax WGS on natural (non-adapted) patient isolates. Using 37
patient isolates from Indonesia, Thailand, and travellers, we assessed the application of CF11-based white blood cell
filtration alone and in combination with short term ex vivo schizont maturation. Although CF11 filtration reduced human
DNA contamination in 8 Indonesian isolates tested, additional short-term culture increased the P. vivax DNA yield from a
median of 0.15 to 6.2 ng ml21 packed red blood cells (pRBCs) (p= 0.001) and reduced the human DNA percentage from a
median of 33.9% to 6.22% (p= 0.008). Furthermore, post-CF11 and culture samples from Thailand gave a median P. vivax
DNA yield of 2.34 ng ml21 pRBCs, and 2.65% human DNA. In 22 P. vivax patient isolates prepared with the 2-step method,
we demonstrate high depth (median 654X coverage) and breadth ($89%) of coverage on the Illumina GAII and HiSeq
platforms. In contrast to the A+T-rich P. falciparum genome, negligible bias was observed in coverage depth between
coding and non-coding regions of the P. vivax genome. This uniform coverage will greatly facilitate the detection of SNPs
and copy number variants across the genome, enabling unbiased exploration of the natural diversity in P. vivax populations.
Citation: Auburn S, Marfurt J, Maslen G, Campino S, Ruano Rubio V, et al. (2013) Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput
Whole Genome Sequencing. PLoS ONE 8(1): e53160. doi:10.1371/journal.pone.0053160
Editor: Erika Martins Braga, Universidade Federal de Minas Gerais, Brazil
Received August 6, 2012; Accepted November 26, 2012; Published January 4, 2013
Copyright:  2013 Auburn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded in part by a Wellcome Trust Senior Research Fellowship in Clinical Science awarded RP (RP, SA) and part by the Asia Pacific
Malaria Elimination Network (RP, SA), the Wellcome Trust (DK, GM, SC, VRR, MM, DA, B. MacInnis, OM), the Bill and Melinda Gates Foundation (DK, GM, SC, VRR,
MM, DA, B. MacInnis, OM), the Medical Research Council United Kingdom (DK, GM, SC, VRR, MM, DA, B. MacInnis, OM), the National Health and Medical Research
Council, Australia (NA, JM), and a Swiss National Science Foundation Career Development Fellowship (JM). The Shoklo Malaria Research Unit (KS, FN) is part of the
Mahidol-Oxford-University Research Unit, supported by the Wellcome Trust of Great Britain. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sarah.auburn@menzies.edu.au
Introduction
Plasmodium vivax is a major global health burden. An estimated
2.85 billion people live at risk of infection [1]. Rising levels of
multidrug resistance and severe disease have refocused efforts to
better understand and control vivax malaria [2–8]. One factor
hindering investigations into the biology of P. vivax has been the
inability to maintain this species in continuous culture and
subsequent reliance on expensive primate models. Although
primate adapted strains of P. vivax such as Salvador-1 (Sal-1) have
greatly facilitated molecular studies of the parasite, especially in
the production of the first WGS for this species [9,10], it is
important that future studies focus on the WGS of P. vivax strains
currently affecting human populations [11]. Certainly high-
throughput sequencing technologies [12–14] now provide exciting
opportunities to undertake affordable, high-depth whole-genome
sequencing of hundreds of Plasmodium parasites. The capacity of
this approach has been demonstrated in Plasmodium falciparum, with
whole genome sequencing on 227 P. falciparum parasites from
across the globe [15]. A similar approach for P. vivax is critical to
provide insights into the molecular mechanisms underlying drug
resistance, disease severity, and the development of the dormant
(hypnozoite) liver stage.
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However, sequencing Plasmodium parasites using high-through-
put, shotgun-based methodologies are highly challenging. In
addition to the challenges of mapping short-read sequence data
and achieving uniform coverage across the genome, low parasit-
aemias and an abundance of ‘‘contaminating’’ human DNA
present critical technical challenges to sample library preparation
and data yield. The technical challenges are even greater for P.
vivax than for P. falciparum, owing to restricted in vitro culture and
log order lower P. vivax peripheral parasitaemias.
Several approaches have been described for reducing human
DNA contamination in malaria samples. Flow cytometry [16] and
hybrid selection [17,18] methods have demonstrated effective
reduction of human DNA in stored blood and DNA samples,
respectively, with promising prospects for analysis of archived
samples. For higher sample throughput applications, in field
settings where standard laboratory facilities are available for
immediate sample processing, methods based on separation or
filtration of the white blood cell (WBC) fraction from fresh whole
blood offer a more practical and cost-effective approach
[11,15,19–22]. The most cost-effective and perhaps most widely
used filtration method utilises home-made cellulose fibre-based
constructs (CF11 columns) [11,20,22]. Sriprawat and colleagues
have described the efficacy of WBC depletion by CF11 filtration in
P. vivax and demonstrated the method to be efficient at a cellular
level [20]. However, the diploid human genome (,6.4 Gb) within
each WBC is .200 times larger than the haploid P. vivax genome
(,28 Mb) of an infected red blood cell (RBC), hence, the
efficiency of this approach at the molecular level (percentage of
human DNA and P. vivax DNA yield) was unclear. Dharia and
colleagues applied CF11 filtration to produce a high P. vivax
sequence yield on the Illumina Genome Analyzer (GA) platform
[11], but despite a very high parasite density (,100,000 parasites
ml21), approximately 50% of the sequence reads mapped to the
human genome, raising uncertainty regarding the efficacy of their
approach on lower parasitaemia infections.
Within the framework of genome-wide drug resistance studies,
we addressed both human DNA contamination and P. vivax DNA
yield at the molecular level in clinical isolates with a broad range of
parasite densities. We present the efficacy of two sample
preparation approaches, a) CF11 filtration alone (to deplete the
human WBC content), and b) CF11 filtration followed by schizont
maturation in short-term ex vivo culture (to enhance the parasite
yield). Using the Illumina GAII platform, we assess the sequence
yield and coverage distributions in 26 processed isolates including
24 pure P. vivax isolates and 2 mixed-species P. vivax+P. falciparum
infections.
Materials and Methods
Sample Collection
Samples were collected from patients presenting with uncom-
plicated P. vivax malaria as determined by microscopy at the Royal
Darwin Hospital, Australia (returning travellers), the Rumah Sakit
Mitra Masayarat Hospital in Papua Indonesia, and the Shoklo
Malaria Research Unit in Thailand. All samples were collected
from patients presenting to outpatient clinics with P. vivax
parasitaemia as determined by microscopy. Exclusion criteria
included severe malaria, administration of anti-malarial or
antibiotic treatment in the previous 2 weeks, and age less than 3
years. The volume of venous blood collected was tiered by patient
age and weight. In children (age ,5 years), blood volumes were
specified as 1 ml blood per kg body weight, with a maximum of
6 mls. In children .5 years of age and adults, 12 and 18 mls were
drawn, respectively. All blood samples were drawn into lithium
heparin VacutainerTM tubes (Becton-Dickinson).
Ethical Approval
All biological samples and patient data were collected with
written, informed consent from the patient or a parent or
guardian. Ethical approval for this study was obtained from the
Human Research Ethics Committee of the NT Department of
Health & Families and Menzies School of Health Research,
Darwin, Australia (HREC 09-83), the Eijkman Institute Research
Ethics Commission (EIREC 2010-47), the Ethics Committee of
the Faculty of Tropical Medicine, Mahidol University, Thailand
(MUTM 2006-029) and the Oxford Tropical Research Ethics
Committee, Oxford University, UK (OXTREC 27-05).
White Blood Cell Depletion
All samples were processed within 6 hours of venepuncture. The
plasma and buffy coat layer were removed after separation by
centrifugation at 1,500–2,000 rpm for 10–15 minutes at ,22uC.
The remaining pellet was resuspended in an equal volume of
phosphate-buffered saline (PBS) and subject to CF11 (Whatman)
filtration, as previously described [20]. Briefly, the re-suspended
blood was added to a CF11 column which had been pre-washed
with PBS, and the RBCs were gently washed through with PBS
until the liquid dripping into the collection tube was clear. The
filtered blood sample was then centrifuged at 1000 rpm for 5
minutes, the supernatant was removed, and the pellet was re-
suspended in an equal volume of PBS. The filtration process was
then repeated with a new CF11 column. After the study was
completed, Whatman discontinued the production of CF11.
However, as discussed elsewhere [23], unpublished trials in P.
vivax field isolates indicate that medium-sized cellulose fibre
powders available from other companies (e.g. Sigma product
number C6288), provide equivalent leukocyte retention to What-
man CF11. In a subset of the Indonesian and returning traveller
samples, aliquots were collected at different stages of blood
processing. A summary of the sample numbers available for each
processing step and study site is presented in Table 1.
Schizont Maturation: Short-term ex vivo Culture
After double CF11 filtration, the parasites in the remaining
RBC preparation were cultured ex vivo to enable early blood stages
to mature to schizonts, as described elsewhere [24]. Incomplete
culture medium was prepared with McCoy’s 5A medium
supplemented with HEPES (25 mM), L-glutamine (2 mM),
gentamicin (40 mg/L) and D-glucose (0.24%). Twenty percent
AB+ human serum (inactivated at 56uC for 30 mins) was added to
the incomplete medium to prepare the complete medium. The
RBC pellet was added to complete medium at a 2% haematocrit.
The resultant blood medium mixture was split accordingly into
culture flasks (75 cm3) and incubated at 37.5uC for ,40–48 hours,
using a candle jar to control O2 and CO2 levels. After culture, the
RBC pellet was obtained by centrifugation at 2,000 rpm for 10
minutes. Thick and thin blood films were made on pre-, peri- and
post-culture samples in order to monitor the extent of parasite
maturation in culture.
DNA Extraction and Human and P. vivax DNA
Quantification
DNA was extracted from the RBC pellets using QIAamp Blood
Midi or Maxi kits (Qiagen) as per the manufacturer’s protocol.
Plasmodium species was confirmed by PCR and real-time quanti-
tative PCR (RT-qPCR) [25,26]. Total sample DNA concentration
P. vivax Preparation WGS
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was measured using Invitrogen’s Quant-iTTM dsDNA HS assay as
per the manufacturer’s protocol.
The percentage of human (and P. vivax) DNA in the Indonesian
and traveller samples was estimated by RT-qPCR with human
(Toll-like receptor 9 [TLR9]) and P. vivax (P. vivax fructose 1, 6-
bisphosphate aldolase [pvaldo]: PVX_118251) specific primers. Primer
sequences (5’-3’) were as follows: TLR9-F: ACGTTGGATG-
CAAAGGGCTGGCTGTTGTAG, TLR9-R: ACGTTG-
GATGTCTACCACGAGCACTCATTC, pvaldo-F: GA-
CAGTGCCACCATCCTTACC, pvaldo-R:
CCTTCTCAACATTCTCCTTCTTTCC. The Indonesian sam-
ples were processed at the Eijkman Institute, and the traveller
samples were processed at the Menzies School of Health Research.
Cloned plasmid TLR9 and pvaldo fragments surrounding the
targeted RT-PCR amplicons were generated as standards for the
assays using the TOPO TA CloningH Kit (Invitrogen). The
plasmids were diluted as appropriate to encompass the expected
concentration range of the test samples. Separate SYBRH Green-
based reactions comprising 1 ml DNA template, 2x SensiMix No
Ref (Quantace), 200 nM each primer, and Nuclease-free water to a
10 ml final volume, were prepared for each of the TLR9 and pvaldo
assays and run on a Corbett Rotor-Gene 6000 machine with the
following cycle conditions: 1695uC/15 mins; 406 (95uC/30 sec;
60uC/30 sec; 72uC/45 sec); 1668uC - 90uC in 0.5uC increments.
All samples and standards were run in duplicate. The concentra-
tion of the test sample’s TLR9 and pvaldo amplicons were
approximated by standard curve analysis using the Corbett
Rotor-Gene 6000 series software 1.7. In order to calculate the
relative proportions of human and P. vivax DNA, the estimated
concentration of P. vivax DNA was multiplied by a factor of ,0.01
to account for the relative differences in the size of the TLR9
(4550 bp) and pvaldo (3115 bp) plasmids, and the human
(,3.2 Gb) and P. vivax (,28 Mb) genomes. The percentage of
human DNA was calculated using the adjusted P. vivax DNA
quantity.
In the Thai samples, the percentage of human DNA was
estimated at the Wellcome Trust Sanger Institute using a RT-
qPCR assay with human standards and primers [19]. The P. vivax
DNA quantity was then extrapolated as the total DNA quantity
minus the estimated human DNA quantity.
Statistical Analysis
Excluding the mixed-species infections, the significance of the
difference between Indonesia (n=15) and Thailand (n=19) in
each of ex vivo culture duration, percentage of schizonts post-
CF11+ culture, percentage of human DNA post-CF11+ culture,
and P. vivax DNA yield post-CF11+ culture was assessed using the
Mann-Whitney U test.
Using the Indonesian isolates for which both pre- and post-
culture aliquots were available (n=8), the Wilcoxon signed-rank
test was used to assess the difference between paired pre- and post-
culture isolates in each of human DNA percentage and P. vivax
yield.
Comparisons between the RT-qPCR and Illumina estimates of
human DNA percentage were undertaken on data derived from
the post-CF11+ culture aliquots of the pure P. vivax isolates (n=22
[3 Traveller, 19 Thailand]) for which Illumina sequence was
available (see Table 1). The correlation between the RT-qPCR
and Illumina human DNA percentage estimates was assessed using
Spearman’s rank correlation coefficient. The significance of the
difference in magnitude between the percentage of human DNA
determined by RT-qPCR and Illumina was assessed using the
Wilcoxon signed-rank test. Significance for all tests was deter-
mined at the 5% threshold. All analyses were undertaken using R
software [27].
Whole Genome Sequencing: Library Preparation and
Sequencing
Twenty-four pure P. vivax and 2 P. vivax+P. falciparum infections
(see Table 1) were sequenced on the Illumina GA II or HiSeq
2000 platform (see Table S1) (http://www.illumina.com/systems/
genome_Analyzer.ilmn) at the Wellcome Trust Sanger Institute.
Pre- and post-culture aliquots were sequenced for two of the pure
P. vivax isolates, leaving 22 independent samples (see Table 1).
Paired-end multiplex or non-multiplex (see Table S1) libraries
were prepared from 500 ng - 1 mg total DNA, as per the
manufacturer’s protocol, with the exception that genomic DNA
was fragmented using Covaris Adaptive Focused Acoustics rather
than nebulisation. Multiplexes comprised 12 tagged samples.
Cluster generation and sequencing were undertaken as per the
manufacturer’s protocol for paired-end 75 bp, 76 bp or 100 bp
sequence reads (see Table S1).
Sequence Alignment and Coverage Statistics
The total yield of raw, unaligned, sequence data was recorded
for each sample. The data was then aligned against each of the P.
vivax Sal-1 (PlasmoDB release 9.1 [http://plasmodb.org/
Table 1. Summary of Samples and Processing Methods.
Samples/Sites Species Preparation Sequencing
4 Traveller (Darwin) 3 P. vivax 3 Unprocessed –
3 Post-CF11 b 2
a 3 Post-CF11+ Culture 3
1 P. vivax+P. falciparum 1 Post-CF11 1
15 Indonesia 15 P. vivax 8 Post-CF11 –
15 Post-CF11+ Culture –
20 Thailand 19 P. vivax 19 Post-CF11+ Culture 19
1 P. vivax+P. falciparum 1 Post-CF11 1
37 P. vivax 24 P. vivax (22 independent)
2 P. vivax+P. falciparum 2 P. vivax+P. falciparum
aOne isolate failed culture. b Excluded sample aliquot from the isolate which failed culture.
doi:10.1371/journal.pone.0053160.t001
P. vivax Preparation WGS
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common/downloads/release-9.1/PvivaxSaI1/fasta/data/
PlasmoDB-9.1_PvivaxSaI1_Genome.fasta] [10], and NCBI acces-
sion AB649419.1 [apicoplast genome: http://www.ncbi.nlm.nih.
gov/nuccore/AB649419.1] [28]), P. falciparum (3D7 PlasmoDB
release 9.1 (apicoplast genome included) [http://plasmodb.org/
common/downloads/release-9.1/Pfalciparum3D7/fasta/data/
PlasmoDB-9.1_Pfalciparum3D7_Genome.fasta] [29]), and Homo
sapiens (NCBI build V37 [30]) reference genomes using the bwa
read mapping algorithm (version 0.6.2), with the default execution
parameters (available from http://bio-bwa.sourceforge.net) [31].
The percentage of reads mapping against each of the P. vivax, P.
falciparum, and human genomes was derived from the resultant bam
alignment files and recorded for each sample [32]. The P. vivax bam
files (and P. falciparum bam files for the 2 mixed-species samples)
were analysed further with the ‘depth’ command provided in the
SAMtools application (version 0.1.18) to compute the per-base
depth. The default SAMtools depth parameters were used with the
exception of the mapping quality threshold (Q) of 20, correspond-
ing to 1% mapping error). The resultant depth files were processed
using R software [27] to derive summary statistics on sequence
depth (fold-coverage of a given region) and breadth (percentage of
a given region covered by a given number of reads). Breadth
statistics were derived for a minimum of 1 and of 20 reads.
Breadth and depth statistics were determined for the full nuclear
reference genome (i.e. excluding the mitochondrial and apicoplast
sequences) and coding and non-coding regions. Coding and non-
coding positions were defined in each of P. vivax and P. falciparum
with the Sal-1 PlasmoDB release 9.1 (http://plasmodb.org/
common/downloads/release-9.1/PvivaxSaI1/gff/data/PlasmoDB-
9.1_PvivaxSaI1.gff) and 3D7 PlasmoDB release 9.1 [http://
plasmodb.org/common/downloads/release-9.1/Pfalciparum3D7/
fasta/data/PlasmoDB-9.1_Pfalciparum3D7_Genome.fasta] anno-
tation files, respectively. Summary plots were generated using R
software [27].
Results
Samples
In total, 39 independent P. vivax isolates were processed: 4 from
returning travellers, 15 from Indonesian patients and 20 from
Thai patients (Table 1). One of the returning traveller isolates
(Papua New Guinea) and one of the Thai isolates were found to be
mixed-species infections of P. vivax and P. falciparum by PCR and
thus were not included in the sample preparation analyses. In the
remaining 37 pure P. vivax samples, parasite densities ranged from
2,600 to 99,480 parasites ml21, with a median of 18,640 parasites
ml21 (Figure 1A). Sampling was undertaken largely within the
framework of a complementary study investigating P. vivax ex vivo
drug susceptibility testing, which requires processing predomi-
nantly ring stage parasites (see [24]). Therefore the majority of
samples in the current molecular study exhibited a high proportion
of ring stage parasites (median 94% [range: 7–100%]) (Figure 1B).
Short-term ex vivo culture was successful in all except one sample
(DRW-002), the median duration of incubation being 43.5 hours
[range: 39–53] with a final median percentage of schizonts of 52%
[range: 12–88%] (Figure 1C and D). The median incubation
period in the Thai samples (42.5 hours [range: 40–46]) was
significantly shorter than in the Indonesian samples (median= 48
hours [range: 43–53) (Mann-Whitney U test: p=5.661027). In
addition, the Thai samples produced a greater percentage of
schizont stages (median= 63% schizonts [range: 27–88]) than the
Indonesian samples (median= 42% [range: 20–80]) (Mann-
Whitney U test: p=661027). Details on the clinical and
laboratory properties of each sample are presented in (Table S2).
Percentage Human DNA (RT-qPCR)
In each of the Indonesian, Thai and traveller sample sets, the
distribution of human DNA percentages (as defined by RT-qPCR)
at each processing step is illustrated in Figure 2. The human DNA
contamination assessed in three samples from travellers prior to
processing showed all samples to have .90% human DNA. After
CF11 filtration, human DNA contamination fell from a median of
95.2% [range: 91.9–99.4] to 54.6% [range: 24.3–60.6]. This
dropped further to a median of 38.1% [range: 6.29–56.5]
following short-term culture.
The impact of the short term culture step relative to CF11
filtration alone was further assessed in 8 Indonesian isolates with
paired pre- and post-culture aliquots, and found to reduce human
DNA by 4.91-fold [range: 1.87–13.48]; from a median of 33.9%
[range: 1.58–68.6] in post-CF11 samples to 6.22% [range: 0.20–
23.0] following culture (p=0.008). Of the 3 traveller and 8
Indonesian samples, 81.8% (9/11) of the post-culture aliquots
exhibited less than 30% human DNA, in contrast to 45.5% (5/11)
of the post-CF11 aliquots.
In the full set of 37 post-CF11+ culture samples, the median
human DNA content was 3.85% [range: 0.20–56.5]. The median
human DNA percentage in the post-CF11+ culture Thai samples
was 2.65% [range: 0.40–53.4]. This was lower than in the full set
of 15 post-CF11+ culture Indonesian samples (4.31% [range:
0.20–44.6]) but the difference was not significant (p=0.086).
P. vivax DNA Yield
In each of the Indonesian, Thai and traveller sample sets, the
distribution of the P. vivax DNA yield at each processing step is
illustrated in Figure 3. In the 3 unprocessed samples from
returning travellers, the median P. vivax DNA yield was
1.29 ng ml21 packed red blood cells (pRBCs)[range: 0.36–3.93],
rising to 1.71 ng ml21 pRBCs [range: 0.24–1.91] following CF11
filtration, and 2.00 ng ml21 pRBCs [range: 0.57–3.82] following
the addition of short term culture.
In the 8 Indonesian isolates with paired pre- and post-culture
aliquots, the P. vivax DNA yield increased a median 34-fold from a
median of 0.15 ng ml21 pRBCs [range: 0.01–1.39] in the post-
CF11 aliquots to a median of 6.2 ng ml21 pRBCs [range: 2.34–
14.4] after additional culture (p=0.001). Extrapolating from the
yield estimates per microliter pRBCs, in a ‘‘standard’’ 5 ml (50%
haematocrit) whole blood sample, amongst the 3 traveller and 8
Indonesian isolates, 100% of the post-culture aliquots would give a
sufficient P. vivax DNA yield ($500 ng) for Illumina genome
sequencing compared to 54.5% (6/11) of the post-CF11 aliquots.
Including the human DNA yield, 72.7% (8/11) of the post-CF11
aliquots would yield sufficient total DNA for whole genome
sequencing. Considering both the yield of total DNA (500 ng
threshold) and percentage of human DNA (30% threshold), 81.8%
(9/11) of the post-culture aliquots would meet the requirements for
whole genome sequencing in contrast to 36.4% (4/11) of the post-
CF11 aliquots.
In the full set of 37 post-CF11+ culture samples, the median P.
vivax DNA yield was 3.12 ng ml21 pRBCs [range: 0.56–14.4]. The
median yield in the Indonesian samples (5.33 ng ml21 pRBCs
[range: 0.56–14.4]) was significantly higher than in the Thai
samples (2.34 ng ml21 pRBCs [range: 0.64–6.61]) (p=0.010).
Sequence Data: Yield and Alignment
Sequence data was successfully generated on 22 post-CF11+
culture P. vivax isolates, 2 post-CF11 (pre-culture) P. vivax sample
aliquots, and 2 mixed-species P. vivax+P. falciparum isolates.
The data are available in the European Nucleotide Archive (ENA)
(http://www.ebi.ac.uk/ena/data/search?query=plasmodium) [33].
P. vivax Preparation WGS
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For ethical purposes, the data submitted to the ENA are filtered to
remove the human alignments. Sample accession numbers for the
raw data are presented in (Table S3). Details of the sequence yield
and mapping statistics for each sample are presented in (Table S1).
The median yield of total sequence data generated was 2321 million
bases (Mb) [range: 902–6911 Mb]. The observed variation in total
sequence yield may reflect variation in a range of factors including
read length, platform (Illumina GAII versus HiSeq) and multiplex
versus non-multiplex sequencing (see Table S1). Figure 4 presents
bar-plots illustrating the distribution of reads which aligned against
each of the P. vivax, human, and P. falciparum reference genomes, as
well as ‘‘other’’, non-aligned reads, in each sample. In the 22
independent, pure P. vivax samples, the median percentage of reads
which mapped to the P. vivax reference was 79.7% [range: 11.0–
89.1]. Across these samples, the median sequence depth was 54X
[range: 18–116X], as illustrated in Figure 5. In terms of read breadth,
the median percentage of the P. vivax reference covered by a
minimum of 1 base was 90.9% [range: 89.1–92.6%], dropping to a
median of 86.9% [range: 45.6–89.1%] covered by a minimum of 20
bases (Figure 6).
As expected, the percentage of reads which mapped against the
human reference was positively correlated with the percentage of
human DNA estimated by RT-qPCR (rho= 0.94, p=4.7610211)
in the 22 independent pure P. vivax isolates. The percentage of
human reads was only a median 1.34-fold [range: 0.35–4.02-fold]
higher than the RT-qPCR estimates of human DNA. However,
Figure 1. Distribution by sample origin of A) parasite density, B) % ring stage parasites pre-culture, C) duration of ex vivo schizont
maturation, and D) % schizont stage parasites post-culture. Vertical lines indicate median of distribution.
doi:10.1371/journal.pone.0053160.g001
P. vivax Preparation WGS
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the difference between the median percentage of human reads
(4.40% [range 0.18–83.2%]) and RT-qPCR human DNA
estimates (2.7% [range 0.40–56.5%]) was significant (p=0.0053).
Also as expected, the post-CF11 aliquots of DRW-001 and DRW-
003 demonstrated a substantially higher median percentage of
human reads (2.55 and 5.36-fold difference, respectively) and
accordingly lower median P. vivax read depth (2.14 and 3.76-fold
difference, respectively) than their respective post-culture aliquots
(Table 1).
In the 22 independent, pure P. vivax samples, a median of 0.30%
reads [range: 0.17–0.61%] mapped to both the P. vivax Sal-1 and
P. falciparum 3D7 reference genomes. The median percentage of
Figure 2. Distribution of human DNA quantity (%) by sample origin and blood processing step. Vertical lines indicate median of
distribution.
doi:10.1371/journal.pone.0053160.g002
Figure 3. Distribution of P. vivax yields (ng ml21 packed RBCs) by sample origin and blood processing step. Vertical lines indicate
median of distribution.
doi:10.1371/journal.pone.0053160.g003
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reads which did not map to the human, Sal-1 or 3D7 reference
genomes (‘‘other’’) in these samples was 14.4% [range: 5.79–
20.0%].
Sequence Data: Uniformity of Coverage
The coding and non-coding sequence depth distributions for P.
falciparum and P. vivax in the 2 mixed-species sample are presented
in Figure 7. In both samples, the P. vivax non-coding and coding
sequences peaked at similar depths of coverage (56 and 59
respectively in THA-009; both 5 in DRW-004), close to the
expected (nominal) sequence depths (53.0 and 5.5 in THA-009
and DRW-004, respectively). In contrast, the P. falciparum non-
coding sequences peaked at moderately lower depth than the
corresponding coding sequences (14 and 29 respectively in THA-
009; 22 and 36 respectively in DRW-004) and nominal sequence
depths (24.3 and 29.8 in THA-009 and DRW-004, respectively).
The coding and non-coding coverage distributions in the 22 pure
P. vivax samples (Figure S1) confirmed this reduced coverage bias
across the P. vivax genome.
Discussion
Limited parasite DNA and extensive human DNA contamina-
tion present major challenges to high-throughput genomic analysis
of clinical P. vivax isolates. We demonstrate the efficacy of a simple
two-step CF11 filtration+schizont maturation method in yielding
samples with low human contamination and high parasite yield.
Using the Illumina GAII platform, we confirm high P. vivax
sequence yield and uniform coverage across the genome in natural
patient isolates prepared using this two-step method. Additional
sequence data from 2 mixed P. vivax+P. falciparum infections
demonstrated potential for accurate WGS analysis of both species
in mixed infections.
The simplicity and low resource intensity of the CF11 filtration
procedure was highly practical for processing isolates in field
settings. However, in 8 paired Indonesian isolates, the filtration
step alone provided only moderate reduction in human DNA
percentage (to a median of 33. 9%) and resulted in a low P. vivax
DNA yield (median 0.15 ng ml21 pRBCs). The additional process
of short-term ex vivo culture, whilst less simple and requiring more
resources than filtration alone, reduced the percentage of human
DNA to a median of 6.22% and increased the parasite DNA yield
Figure 4. Distributions of Illumina Read Alignments against the P. vivax, Human, and P. falciparum Reference Genomes. *Mixed-species
confirmed by PCR. **Poor maturation in ex vivo culture. Note: % P. vivax reads does not include reads which cross-map against P. falciparum.
doi:10.1371/journal.pone.0053160.g004
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to a median of 6.2 ng ml21 pRBCs. It should be noted that the
short-term culture step facilitates sample preparation not only
through enhancement of P. vivax yield but also through further
depletion of the remaining WBCs which have been observed to
adhere to the internal surfaces of plastic culture flasks (unpublished
data).
A minimum of 500 ng DNA generally ensures effective library
preparation on the Illumina platform. Libraries have been
prepared with lower quantities but the risk of failure increases
with decreasing DNA quantity. In a study addressing Illumina
sequence coverage in WBC-depleted P. falciparum field isolates,
high sequence yields (.40X) were observed in samples with
#30% human DNA [19]. In our study, a third of the post-CF11
samples exhibited #30% human DNA and $500 ng total DNA,
in contrast to more than 80% of the corresponding post-CF11+
culture samples. Therefore, the two-step CF11+ schizont matura-
tion approach ensures a greater probability of successful P. vivax
sample preparation for high-throughput genome sequencing.
However, with continual improvements in sequencing technolo-
gies, the effective human DNA percentage and parasite yield
Figure 5. Sequence Depth Distributions across the P. vivax Sal-1 Reference Genome and in Coding and Non-coding Regions.
Samples = 22 independent, pure P. vivax isolates. CDS= coding sequence.
doi:10.1371/journal.pone.0053160.g005
Figure 6. Sequence Breadth Distributions across the P. vivax Sal-1 Reference Genome and in Coding and Non-coding Regions.
Samples = 22 independent, pure P. vivax isolates. CDS= coding sequence.
doi:10.1371/journal.pone.0053160.g006
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thresholds are anticipated to rise and fall, respectively, improving
the prospects for adopting processing methods that apply CF11
filtration alone. In field settings where even CF11 filtration is not
feasible, developments in DNA-based parasite enrichment meth-
ods such as hybrid selection may present an alternative approach
[17,18].
A potential limitation of the two-step approach is failure of a
sample to mature in ex vivo culture. In our study, possibly as a result
of patient blood sampling at the peak of a paroxysm (41.9uC), one
isolate in a returning traveller failed to mature in short-term
culture. As a result, the difference in the percentage of human
DNA between the post-CF11 (60.63%) and post-CF11+ culture
(56.48%) samples was negligible. Furthermore, in contrast to the
other 10 sample pairs with successful maturation, P. vivax DNA
yield (ng ml21 packed RBCs) was greater post-CF11 (1.71) than
post-CF11+ culture (0.57). This apparent loss of parasite DNA is
likely to reflect parasite death and DNA degradation during the
Figure 7. Comparative Sequence Depth Distributions between the P. vivax and P. falciparum Genome in THA-009 and DRW-004. Plots
indicate the number of bases (y-axis) with a given sequence depth (x-axis) in different regions of the P. vivax (green) and P. falciparum (blue) genome.
Whilst the P. vivax coding and non-coding sequences peak close to the nominal total sequence depth, the P. falciparum coding and non-coding
sequences peak at moderately different coverage depths.
doi:10.1371/journal.pone.0053160.g007
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culture step. Therefore, early termination of culture is advised
following signs of extensive parasite death.
As demonstrated in comparisons between the Thai and
Indonesian samples, variation in maturation efficacy may be
observed between isolates from different origins. Whether this
reflects underlying differences in the biology of P. vivax isolates
from different geographic origins remains to be determined. The
efficacy of short-term P. vivax culture thus requires further
assessment in a broader geographic range of isolates.
Using the Illumina GAII and HiSeq platforms on 22 pure P.
vivax samples prepared using the two-step method, we observed
high depth (median 54-fold coverage) and breadth (median 90.9%
and 86.9% at minimum depth 1 and 20, respectively) of coverage
across the Sal-1 reference genome. Although variation was
observed in the percentage of reads which aligned against the
Sal-1 reference (11–89.1%), the median was moderately high at
79.7%. A large proportion of this variation presumably reflected
the percentage of human reads, which ranged from 0.18 to 83.2%,
emphasizing the importance of effective sample preparation. The
cause of the moderate inflation (median 1.34-fold increase) in the
percentage of human reads relative to the percentage of starting
human DNA remained unclear. A small degree of error in the
human quantification method, or bias in favour of human
sequence during the library preparation, cluster generation and/
or sequencing process might also explain the inflation. The latter
should add further demand for effective sample preparation.
In the 22 pure P. vivax isolates, a low proportion of reads (0.17–
0.61%) aligned against both the P. vivax and P. falciparum reference
genomes. The low frequency of these reads is promising for whole
genome analyses of mixed P. vivax+P. falciparum infections.
However, further characterisation in these regions is required,
including assessment of sequence complexity and gene ontology,
and addressing the influence of varying read mapping thresholds.
The ability to analyse mixed-species infections is critical in
enabling assessment of the reservoir of P. vivax isolates within
mixed-species infections in regions with co-endemic P. vivax and P.
falciparum. Increasing Illumina read lengths should facilitate further
resolution of the species in mixed infections. In the mixed species
samples investigated here, the proportion of P. vivax relative to P.
falciparum isolates were moderate and thus reasonable coverage of
the P. vivax genome was observed. However, in many mixed-
species infections, P. vivax appears to be suppressed by P. falciparum
and hence, the density of the former may be very low [34,35]. In
such samples, short-term culture under conditions favouring P.
vivax maturation may be advisable. Further studies are required to
identify optimal methods for preparing mixed-species infections
for WGS.
In the 22 pure P. vivax isolates, a consistent proportion of reads,
ranging from 5.79–20.0%, did not align against the P. vivax,
human or P. falciparum reference. Further investigations are
required to identify the nature of these ‘‘other’’ reads. A
proportion of the reads may represent highly diverse regions of
the genome. Genomic rearrangements and deletions relative to the
Sal-1 reference, and sequences overlapping currently unaligned
contigs in the Sal-1 reference genome may also account for a
proportion of these reads.
In P. falciparum, non-coding regions of the genome generally
exhibit moderately lower read depth than coding-regions on the
Illumina platform [15,36]. With genome-wide sequence data from
2 mixed-species P. vivax+P. falciparum infections, we had the
opportunity to compare the coverage distribution in coding versus
non-coding regions between the two species with data generated
under the same library preparation, cluster generation and
sequencing conditions. In contrast to P. falciparum, presumably
owing to the lower A+T content in the P. vivax genome (,58%
versus ,81% in P. falciparum), the read depth frequency
distributions in coding and non-coding regions both peaked close
to the expected (nominal) sequence depth. The notable uniformity
of coverage across the P. vivax genome will facilitate the detection
of copy number variants, which have been shown to underlie
important disease-causing or drug resistance mechanisms [37–39].
Furthermore, the ability to access non-coding regions of the
genome using high-throughput sequencing methods is promising
for SNP identification in these regions, which may carry important
determinants of gene expression. In depth SNP analysis is beyond
the scope of the current study, and will be addressed in a separate,
larger scale multi-centre study of P. vivax diversity.
In conclusion, our study describes the efficacy of two alternative
methods for preparing P. vivax field samples for high-throughput
WGS, using currently available technology. The one-step method
offers a more simple and practical approach, but exhibited only
moderate efficacy in reducing human DNA, and limited parasite
DNA yield. The two-step method was more efficient at reducing
human DNA contamination and increasing parasite DNA yield,
although at a greater resource cost. A video demonstration of these
methods is now available online [40]. The demonstration of high
depth, breadth and uniformity of coverage across both coding and
non-coding regions of the genome in effectively prepared P. vivax
field isolates provides an essential opportunity for unbiased
exploration of the natural diversity in P. vivax populations.
Supporting Information
Figure S1 Coding and Non-coding Sequence Depth
Distributions in 22 Independent, Pure P. vivax Isolates.
Plots indicate the number of bases (y-axis) with a given sequence
depth (x-axis) in coding (solid green line) and non-coding (dashed
green line) regions of the P. vivax genome. Dashed grey line
indicates the expected (nominal) sequence depth for each sample.
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Table S1 Sequence Coverage Statistics. Pv= P. vivax;
Pf = P. falciparum; a Multiplexes comprise 12 samples. b Quantita-
tive real-time PCR estimate; c Reads overlapping P. vivax and P.
falciparum. d Expected sequence depth at each position in the P.
vivax genome – calculated as total number of bases sequenced
divided by number of bases in the genome (based on Sal-1
reference genome size ,27 Mb). e Percentage Sal-1 reference
genome covered at given read depth. *Poor maturation during
short-term culture.
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